Aquestive Therapeutics ROA 2024

Aquestive Therapeutics Aktienanalyse

What does Aquestive Therapeutics do?

Aquestive Therapeutics Inc is a biopharmaceutical company based in Warren, New Jersey. The company specializes in the development of drugs for neurological disorders, rare diseases, and other medical needs. It was founded in 2004 and went public in 2018. The company operates in two main business segments: the development of proprietary drugs and the development of film technology for drug delivery. Both segments are closely connected and aim to provide innovative solutions for urgent medical needs. Aquestive's first business segment is the development of proprietary drugs for neurological disorders such as epilepsy, Parkinson's disease, and migraines. The company has various drug candidates in the pipeline, including a film-based sublingual tablet for the treatment of epilepsy and an injection solution for Parkinson's. These drug candidates are designed to complement or improve existing treatment options and achieve higher efficacy and tolerability for patients. Aquestive's second business segment is the development of film technology for drug delivery. Aquestive's patented film technology enables fast and reliable drug administration and can help improve the treatment of many diseases. Aquestive's film technology is particularly designed for drug administration through the mucous membranes of the mouth and throat. This includes film formulations for sublingual, buccal, or oromucosal drug delivery. An example of an Aquestive product is the sublingual film formulation of diazepam, marketed under the trade name Sympazan. Sympazan is approved for the treatment of LGS (Lennox-Gastaut syndrome), a rare and severe form of epilepsy. The sublingual film formulation of diazepam provides rapid onset of action and increased tolerability for patients compared to traditional dosage forms such as tablets or capsules. Aquestive has also specialized in the development of generic drugs for mucous membrane administration. The company produces sublingual, buccal, and oromucosal film formulations for a variety of medications, including drugs for pain, allergies, and nausea. Aquestive's generic drugs offer higher efficacy and tolerability for patients compared to conventional dosage forms such as tablets or capsules. Overall, Aquestive is an innovative company dedicated to improving patients' lives through novel therapeutic approaches. The company specializes in the development of film technology for drug delivery, providing a variety of innovative solutions for urgent medical needs. With its proprietary drug candidates and expertise in film technology, Aquestive is well-positioned to continue offering groundbreaking solutions for medical care. Aquestive Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Aquestive Therapeutics's Return on Assets (ROA)

Aquestive Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Aquestive Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Aquestive Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Aquestive Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Aquestive Therapeutics stock

What is the Return on Assets (ROA) of Aquestive Therapeutics this year?

The Return on Assets (ROA) of Aquestive Therapeutics is -0.14 undefined this year.

What was the ROA of Aquestive Therapeutics compared to the previous year?

The ROA of Aquestive Therapeutics has increased by -85.62% compared to the previous year.

What consequences do high ROA have for investors of Aquestive Therapeutics?

A high ROA is advantageous for investors of Aquestive Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Aquestive Therapeutics?

A low ROA can be unfavorable for investors of Aquestive Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Aquestive Therapeutics affect the company?

An increase in ROA of Aquestive Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Aquestive Therapeutics impact the company?

A reduction in the ROA of Aquestive Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Aquestive Therapeutics?

Some factors that can influence the ROA of Aquestive Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Aquestive Therapeutics important for investors?

The ROA of Aquestive Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Aquestive Therapeutics take to improve ROA?

To improve ROA, Aquestive Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Aquestive Therapeutics pay?

Over the past 12 months, Aquestive Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aquestive Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aquestive Therapeutics?

The current dividend yield of Aquestive Therapeutics is .

When does Aquestive Therapeutics pay dividends?

Aquestive Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aquestive Therapeutics?

Aquestive Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aquestive Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aquestive Therapeutics located?

Aquestive Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aquestive Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aquestive Therapeutics from 10/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/27/2024.

When did Aquestive Therapeutics pay the last dividend?

The last dividend was paid out on 10/27/2024.

What was the dividend of Aquestive Therapeutics in the year 2023?

In the year 2023, Aquestive Therapeutics distributed 0 USD as dividends.

In which currency does Aquestive Therapeutics pay out the dividend?

The dividends of Aquestive Therapeutics are distributed in USD.